Serstech Current Liabilities
The Current Liabilities of Serstech (SERT.ST) as of Jul 25, 2026 is 8.02 M SEK. In the previous year, Current Liabilities was 19.52 M SEK — a change of -58.90% (lower).
Get this data via API
Financial Data API
Current Liabilities
8.02 MSEK
YoY
-58.90%
Last updated:
Current Liabilities of Serstech is 2026 8.02 M SEK. Current Liabilities of Serstech was 2025 19.52 M SEK. It decreases by -58.90% lower compared to the previous year.
Access this data via the Eulerpool API
Serstech Stock analysis
What does Serstech do? Serstech AB is a Swedish company that was founded in 2005. The company is headquartered in Lund, Sweden and currently employs about 40 people. Serstech specializes in the development and manufacturing of mobile analytical instruments used in chemistry, materials science, and pharmaceuticals.
Business model:
Serstech AB has an innovative business model aimed at delivering analytical data quickly and reliably to its customers. The company develops portable handheld devices that allow for rapid identification of materials and substances. The devices are easy to use and can be used in many important industries such as healthcare, food safety, and environmental engineering.
History:
Serstech AB started as a company for laser-based spectroscopy devices for fast and precise analysis of chemical compounds. In 2012, the company launched the Serstech 100 Indicator Raman spectrometer and established itself as a provider of handheld devices for material analysis. Since then, Serstech AB has continued to invest in research and development and has introduced several new devices to the market, including the Serstech 100 Indicator+ and the Serstech ID-X.
Divisions:
Serstech AB has three main divisions: materials science, security industry, and pharmaceuticals. In materials science, the company plays a key role in the manufacturing of innovative materials and analysis of samples prior to production. In the security industry, Serstech offers portable devices for quick identification of hazardous substances. In pharmaceuticals, the focus is on fast analysis of medications.
Products:
Serstech AB offers various products tailored to the needs of its customers. One of the most well-known devices is the Serstech 100 Indicator, a portable Raman spectrometer that enables fast in-situ analysis of materials. The Serstech 100 Indicator+ is an enhanced version of the Serstech 100 with additional software and features. The latest device from Serstech is the Serstech ID-X, a portable device that uses both Raman and infrared spectroscopy to enable rapid identification of materials and substances.
Serstech also provides accessories and software to facilitate analysis with the devices. These include sample holders, cases, and backpacks for secure storage of the devices, as well as software that simplifies the analysis of material samples with the devices.
Conclusion:
Serstech AB is a leading provider of mobile analytical instruments. The company is committed to offering its customers high-quality and reliable solutions for fast analysis of material samples. Serstech has an experienced team of scientists and engineers who continuously work on the development of new products and regularly achieve important technological advances. Serstech is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Serstech stock
Current Liabilities of Serstech is 8.02 M SEK in 2026.
Access this data via the Eulerpool API
Balance Sheet — Serstech
Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets
All Key Metrics — Serstech
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth